ARTICLES LIST

 

Total Results: 16203

Media ID Source Name Media Type Language Media Name Media Description Keywords Keywords Link to Article
1543 National Cancer Institute Html en Adult Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version Expert-reviewed information summary about the treatment of adult acute lymphoblastic leukemia.
red blood cells0.657008
treatment0.69838
cancer treatment0.510853
stored stem cells0.432024
myeloid stem cell0.410543
abnormal cells0.408626
cord).0.586593
immature blood cells0.444877
blast cells0.409519
CNS prophylaxis0.43336
cancer cells0.637541
lymphoid stem cell0.411207
type0.407802
chemotherapy0.418061
PDQ cancer information0.486683
specific cancer cells0.45646
clinical trial search0.434142
white blood cells0.722058
stem cell0.530795
treatment clinical trials0.437953
blood stem cells0.480973
National Cancer Institute0.448039
clinical trials0.958798
mature blood cells0.496196
Natural killer cells0.443636
normal cells0.428739
cancer information summary0.448111
clinical trial0.624583
new treatment0.467045
stem cell transplant0.495713
kinase inhibitor therapy0.4731
Lymphoblastic Leukemia Treatment0.414582
chance leukemia cells0.460746
patients0.42006
blood cells0.731186
bone marrow0.727339
immature cells0.419809
CAR T-cell therapy0.438682
cells0.839029
cancer clinical trials0.459465
acute lymphoblastic leukemia0.946164
radiation therapy0.527726
Treatment Editorial Board0.410648
cancer0.8076
standard treatment0.454915
tyrosine kinase inhibitor0.516075
leukemia cells0.619353
CLICK HERE
1598 National Cancer Institute Html en Nutrition in Cancer Care (PDQ®)–Health Professional Version Expert-reviewed information summary about the causes and management of nutrition problems that occur in patients with cancer.
Oncology Nutrition Dietetic0.634094
obese cancer patients0.674849
World Cancer Research0.619802
Cancer Research Fund0.619994
artificial nutrition0.652387
Community Cancer Centers0.700876
Cancer Program Guidelines0.624097
nutrition status0.695452
nutrition screening0.627502
Nutrition Therapy section0.64247
cancer cachexia therapy0.631345
enteral nutrition0.709727
patients0.881369
cancer patients0.790895
weight loss0.81132
oral nutrition supplements0.689897
immunocompromised cancer patients0.638801
North Central Cancer0.622864
megestrol acetate0.683197
Parenter Enteral Nutr0.674425
nutrition0.853145
cancer survivors0.617965
radiation therapy0.659649
Nutr Clin Pract0.657573
Nutrition Dietetic Practice0.630177
et al.0.712864
treatment0.690326
lean body mass0.682169
parenteral nutrition support0.641552
terminal cancer patients0.643213
PUBMED Abstract0.761858
parenteral nutrition0.727185
Support Care Cancer0.683396
experimental cancer cachexia0.632271
oncology nutrition care0.62028
nutrition care plan.0.617909
health care0.624711
Cancer Treatment Group0.649077
advanced cancer0.631851
Clin Nutr0.671517
cancer patients.0.625985
cancer cachexia0.838737
Clin Oncol0.670786
nutrition support therapy0.618651
systematic review0.80665
Central Cancer Treatment0.648181
Cancer J Clin0.618652
Cancer cachexia syndrome0.625914
cancer0.942013
CLICK HERE
1615 National Cancer Institute Html en Cardiopulmonary Syndromes (PDQ®)–Health Professional Version Expert-reviewed information summary about common conditions that produce chest symptoms. The cardiopulmonary syndromes addressed in this summary are cancer-related dyspnea, malignant pleural effusion, pericardial effusion, and superior vena cava syndrome.
vena cava0.611223
pericardial tamponade0.679952
evidence0.62034
randomized controlled trials0.605832
malignant pleural effusion0.70666
pericardial fluid collection0.700496
significant pericardial effusions0.706328
underlying malignant disorders0.602719
right mainstem bronchus0.652149
chest0.626465
cancer patients0.972375
malignant pericardial effusion.0.719099
Cancer Dyspnea Scale0.624114
subxiphoid pericardial windows0.680282
treatment0.619895
nonmalignant causes0.594571
Pericardial biopsy0.658961
pericardial effusions.0.666377
pericardial sac.0.661251
dyspneic cancer patients0.638184
pericardial sclerosis0.657248
Pericardial friction rubs0.684646
subxiphoid pericardial window0.711885
loculated pleural effusions0.605868
pericardial effusion0.810932
pericardial sac0.692904
advanced lung cancer0.597362
terminally ill patients0.609314
large pleural effusion0.611685
pulmonary function tests0.594337
Pericardial fluid cytology0.702526
inoperable cancer patients0.631248
lung cancer patients0.649316
Recurrent pericardial effusion0.706493
dyspnea0.731471
pericardial masses0.661922
pericardial fluid reaccumulation0.694759
pericardial mesothelioma0.66558
respiratory muscle dysfunction0.634779
inferior vena cava0.596175
nebulized local anesthetics0.604885
pericardial sclerotherapy0.657003
chest pain0.622877
malignant pericardial effusions0.808201
pericardial sclerosis.0.657675
malignant pleural effusions0.666328
pericardial effusions0.86832
chest x-ray0.605659
pericardial drainage0.663513
CLICK HERE
1620 National Cancer Institute Html en Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version Expert-reviewed information summary about the treatment of myelodysplastic/myeloproliferative neoplasms including chronic/juvenile myelomonocytic leukemias and atypical CML.
red blood cells0.768748
cancer treatment0.388453
blood -forming cells0.422515
blast cells0.38801
PDQ cancer information0.4465
clinical trial search0.417483
white blood cells0.789303
myelodysplastic /myeloproliferative neoplasm0.381874
abnormal blood cells0.425458
clinical trials0.736543
mature blood cells0.494148
myelomonocytic leukemia0.471388
chronic myelomonocytic leukemia0.433936
cancer information summary0.411963
clinical trial0.54455
patients0.384599
blood cells0.912354
chronic myelogenous leukemia0.426541
immature cells0.400391
platelets0.382322
NCI PDQ cancer0.377587
supportive care0.382497
Treatment Editorial Board0.386238
treatment0.557882
stored stem cells0.41047
myeloid stem cell0.393162
immature blood cells0.507153
blood stem cell0.390434
cancer cells0.421289
lymphoid stem cell0.393903
Easy bruising0.397179
atypical CML0.383221
treatment clinical trials0.403674
blood stem cells0.764143
National Cancer Institute0.413265
normal cells0.378893
juvenile myelomonocytic leukemia0.471101
new treatment0.442289
white blood cell0.40841
healthy red blood0.434016
bone marrow0.568618
myelodysplastic/ myeloproliferative neoplasms0.38491
cells slowly increases0.413624
cancer clinical trials0.423855
myelodysplastic/myeloproliferative neoplasm0.393131
immature white blood0.444308
treatment options0.378048
leukemia cells0.390336
CLICK HERE
1851 National Cancer Institute Html es Tratamiento del cáncer de tiroides (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del tratamiento del cáncer de tiroides.
siguientes procedimientos0.422153
hormona tiroidea0.492622
bLos ganglios0.448367
Hürthle cell carcinoma0.418971
mínima diseminación0.464789
T4b Enfermedad0.438377
American Cancer Society0.43686
European Thyroid Association0.427771
thyroid disease0.486942
niveles i0.45199
Thyroid Association0.441602
fase iii0.434728
Natl Cancer Inst0.440945
Thyroid calcification0.433055
thyroid with0.432277
Prognostic factors0.431082
≤2 cm0.731745
patients with0.416562
tiroides estadio0.461688
N1a Metástasis0.590742
N1b Metástasis0.55338
American Thyroid Association0.427447
papillary thyroid carcinoma0.534329
tejidos blandos peritiroideos0.507165
glándula tiroides0.891491
tumores papilares0.421501
nivel vii0.450974
Lennard CM0.428158
tiroides tipo0.453807
ablación tiroidea0.436707
French Thyroid Cancer0.436044
M0 T10.439686
thyroid cancer0.993324
cápsula tiroidea0.541937
thyroid carcinoma with0.448553
tejidos blandos subcutáneos0.474653
differentiated carcinoma0.433423
follicular thyroid carcinomas0.439446
thyroid carcinoma depends0.445887
thyroid carcinomas0.753573
Surg Oncol0.439117
pronóstico adverso0.424396
cartílagos tiroides0.469208
Thyroid tumors0.433
estadios tnm0.421127
American Joint Committee0.423622
ganglios linfáticos retrofaríngeos0.70543
lobectomía tiroidea0.423995
AJCC Cancer Staging0.417512
CLICK HERE
1926 National Cancer Institute Html es Tratamiento de la leucemia de células pilosas (PDQ®)–Versión para pacientes Resumen de información revisada por expertos acerca del tratamiento de la leucemia de células pilosas.
células madre0.33069
leucemia linfoblástica aguda0.322509
siguientes afecciones0.302348
hueso compacto0.308819
neoplasias mieloides0.302225
vía oral0.301703
rayos x0.301869
gen braf0.305773
largo plazo0.304831
célula madre mieloide0.311776
National Cancer Institute0.301791
siguientes riesgos0.301225
células pilosas0.98731
Instituto Nacional0.306123
PDQ Tratamiento0.305303
célula madre linfoide0.305127
Linfocitos T0.303214
siguientes problemas0.302353
leucemia mielógena0.31078
Drugs Approved0.301713
Physician Data Query0.306482
anticuerpo monoclonal rituximab0.304903
anticuerpo monoclonal usa0.304464
Hairy Cell Leukemia0.302945
leucemia mieloide aguda0.322517
siguientes enlaces0.301398
célula madre0.330149
células sanguíneas maduras0.327581
ósea elabora células0.315738
CLICK HERE
3517 National Cancer Institute Html en Randomization and Bias in Cancer Clinical Trials Information about randomization and bias in cancer clinical trials.
different treatments0.635974
Single-blinded trials0.587003
treatment0.879587
instance0.449169
simplest trial design0.829657
human choices0.621077
control group0.779296
trial0.855759
example0.496876
points0.446685
different health changes0.763108
randomization0.811688
bias0.660255
Double-blinded trials0.584527
clinical trials0.60736
end0.493376
group0.945379
clinical trial0.755171
phase0.504191
new treatment0.781754
process0.451025
chance0.58412
researchers0.446538
patients0.774398
trial results0.587968
treatment trials0.574174
groups0.737104
investigational group0.633981
people0.445658
way0.48098
healthier patients0.602713
treatment group0.70095
doctors0.497874
unusual side effects0.592351
sicker patients0.596186
standard therapy0.638086
CLICK HERE
15777 National Cancer Institute Html en Research Directions for Childhood Cancer NCI has identified areas for which more research is needed on childhood cancers, including investments in basic research, immunotherapies, and moleculary targeted therapies.
small molecule inhibitors0.412891
childhood cancers0.94672
critical gaps0.332101
major treatment advance0.412137
Pediatric MATCH0.392576
research proposals0.436951
peer review process0.389826
immunotherapy technique0.352473
NCI scientists Lawrence0.622389
chimeric antigen receptor0.460833
cancer cells0.401044
highly trained scientists0.390662
high-priority goal0.343491
cancer research0.527941
best scientific proposals0.421088
pediatric patients0.416725
pediatric cancer0.412777
research areas0.34678
T-cell receptor0.362608
specific disease area0.405285
clinical trials0.669991
immunotherapy treatments0.349585
NCI leadership0.495193
Tumor DNA sequencing0.405564
Pediatric Brain Tumor0.687267
NCI-COG Pediatric Molecular0.487101
NCI-sponsored clinical trials0.416329
cancer immunology0.348212
research funding decisions0.424865
NCI funding opportunities0.589573
rigorous grant application0.388949
NCI portfolio0.493947
rapidly advancing field0.423802
new approaches0.32698
advanced cancers0.402816
research topic0.333717
Pediatric Oncology Branch0.692641
young adult patients0.616776
NCI0.771754
Children’s Oncology0.432835
research category0.33728
Brain Tumor Consortium0.615122
Oncology Group0.433591
NCI’s Steven0.52013
past decade0.330224
NCI Center0.621549
adoptive cell transfer0.42055
CLICK HERE
16145 National Cancer Institute Html es Virus de la enfermedad de Newcastle (PDQ®)–Versión para pacientes Resumen de información revisada por expertos sobre el uso del virus de la enfermedad de Newcastle (VEN) como tratamiento para las personas con cáncer.
células anfitrionas0.602816
Centro Nacional0.427496
inmunitario fabrique anticuerpos0.432469
New Hampshire Avenue0.419687
PDQ Virus0.451192
complicaciones quizás0.416168
Drug Administration0.41221
NCI Best Case0.435079
datos bibliográficos pubmed0.420843
posibles formas0.415768
largo plazo0.415867
mayoría usó células0.468567
fase ii0.489698
único efecto0.414956
National Cancer Institute0.423353
siguientes riesgos0.413615
cepa mth-680.496578
distintos factores0.416278
Instituto Nacional0.505259
acupuntura ayuda0.4111
células tumorales enteras0.475674
Salud Complementaria0.443057
sustancias llamadas citocinas0.426511
Visuals Online0.413937
complementarias revisa0.419519
Physician Data Query0.480164
cuarto estudio0.414722
Estados Unidos0.771775
células enteras0.494193
libre uso0.416835
página manejo0.41298
¿El tratamiento0.429077
¿Los beneficios0.412098
juntos cam0.411689
suficientes resultados prometedores0.425777
células renales0.45757
Series Program0.411543
medicina complementaria0.961806
CLICK HERE
16811 National Cancer Institute Html es Cartílago (bovino y de tiburón) (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos sobre el uso de cartílago bovino y de tiburón como tratamiento para personas con cáncer. Nota: la información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.
Shirai E0.323137
cancer treatment0.318107
relation with cartilage-derived0.318214
Langer R0.391189
Enomoto M0.357345
Prudden JF0.438802
Biol Chem0.333806
shark cartilage0.967013
shark cartilage with0.323621
Biol Response Mod0.535917
Cartilage-derived growth factor0.322107
tumor angiogenesis0.329827
cultured endothelial cells0.316222
Cancer Res0.3293
inhibitor from shark0.3338
Natl Cancer Inst0.381802
novel shark cartilage0.322776
shark cartilage extract0.362678
with cartilage-derived anti-tumor0.3188
powdered shark cartilage0.321655
Japanese shark cartilage0.32145
with cartilage-derived0.324288
Biophys Res Commun0.316215
Biochem Biophys Res0.31677
inhibits tumor neovascularization0.319919
Biol Int Rep0.323384
stem cell0.318383
potent shark cartilage-derived0.318104
Takigawa M0.353102
tumor growth0.323007
cartilage extract0.364849
anti-angiogenic antitumor factor0.318413
stem cell assay0.317911
Cell Biol Int0.327732
its relation with0.316418
cell line produces0.317193
Exp Med Biol0.323654
from cartilage0.324423
shark cartilage-derived angiogenesis0.320509
New York0.316148
antitumor factor0.334004
endothelial cell0.365475
Cell Biol0.339136
cartílago bovino0.480214
cartilage contains inhibitors0.320628
angiogenesis inhibitor from0.364307
from shark cartilage0.349703
Sudhalter J0.330756
from japanese shark0.31927
CLICK HERE

 

 

 

Terms of Use | Privacy Policy
©2017 ARCHES Technology. All Rights Reserved.